Phase 1-2 dose-ranging trial of TLK286 (TELCYTA) and Cisplatin (C) as first-line treatment in advanced non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Papadimitrakopoulou, V
Edelman, M
Zinner, R
Blumenschein, G
Jones, S
Willcutt, N
Keck, J
Brown, G
Burris, H
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Maryland, Greenbaum Canc Ctr, Baltimore, MD 21201 USA
[3] Sarah Cannon Canc Ctr, Nashville, TN USA
[4] Telik Inc, Palo Alto, CA USA
来源：
LUNG CANCER | 2005年 / 49卷
关键词：
D O I：
10.1016/S0169-5002(05)81043-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S262 / S263
页数：2
相关论文
共 50 条
  • [1] Phase I-II trial of TLK286 (telcyta), carboplatin (C), and paclitaxel (P) as first-line treatment for advanced non-small cell lung cancer (NSCLC)
    Sequist, L
    Fidias, P
    Temel, J
    Kennedy, E
    Ostler, P
    Rabin, M
    Huberman, M
    Keck, J
    Brown, G
    Lynch, T
    [J]. LUNG CANCER, 2005, 49 : S269 - S269
  • [2] Phase II dose-ranging study of TLK286 a novel glutathione analog prodrug, in combination with cisplatin as first-line treatment in locally advanced or metastatic non-small cell lung cancer (NSCLC).
    Burris, HA
    Edelman, MJ
    Stewart, D
    Fossella, F
    Jones, S
    Willcutt, N
    Keck, JG
    Brown, GL
    Papadimitrakopoulou, V
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 651S - 651S
  • [3] Phase 1-2a dose ranging study of TLK286 (Telcyta™, a novel gluthathione analog) in combination with docetaxel in platinum-resistant non-small cell lung cancer (NSCLC).
    Papaclimitrakopoulou, V
    Zinner, R
    Blumenschein, G
    King, L
    Boasberg, P
    Keck, J
    Mascavage, J
    Jameson, A
    Patel, K
    Parra, R
    Brown, GL
    Hanna, N
    [J]. CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6241S - 6241S
  • [4] Phase I-II trial of TLK286, a novel glutathione analog prodrug, in combination with carboplatin (C) and paclitaxel (P) as first-line treatment for advanced non-small cell lung cancer (NSCLC).
    Sequist, LV
    Fidias, P
    Temel, J
    Kennedy, BA
    Ostler, PA
    Rabin, MS
    Huberman, M
    Keck, J
    Brown, GL
    Lynch, TJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 689S - 689S
  • [5] Phase II trial of gemcitabine and cisplatin as first-line treatment of advanced non-small cell lung cancer (NSCLC).
    Lee, NS
    Byun, JH
    Bae, SB
    Kim, CK
    Lee, KT
    Park, SK
    Park, KK
    Won, JH
    Hong, DS
    Park, HS
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 701S - 701S
  • [6] Phase 1-2a dose ranging study of TLK286 (a novel glutathione analog) in combination with docetaxel in platinum-resistant non-small cell lung cancer (NSCLC).
    Papadimitrakopoulou, V
    Boasberg, P
    Figlin, R
    Zinner, R
    Blumenschein, G
    King, L
    Truong, M
    Patel, K
    Brown, GL
    Hanna, N
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 651S - 651S
  • [7] A phase II trial of adding cetuximab to cisplatin and gemcitabine as first-line therapy in advanced non-small cell lung cancer (NSCLC)
    Barata, F.
    Parente, B.
    Teixeira, E.
    Costa, A.
    Fernandes, A.
    Pimentel, F. L.
    Carvalho, L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [8] Phase 1-2a Multicenter Dose-Ranging Study of Canfosfamide in Combination with Carboplatin and Paclitaxel as First-Line Therapy for Patients with Advanced Non-small Cell Lung Cancer
    Sequist, Lecia V.
    Fidias, Panos M.
    Temel, Jennifer S.
    Kolevska, Tatjana
    Rabin, Michael S.
    Boccia, Ralph V.
    Burris, Howard A.
    Belt, Robert J.
    Huberman, Mark S.
    Melnyk, Ostap
    Mills, Glenn M.
    Englund, Craig W.
    Caldwell, David C.
    Keck, James G.
    Meng, Lisa
    Jones, Marsha
    Brown, Gail L.
    Edelman, Martin J.
    Lynch, Thomas J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (11) : 1389 - 1396
  • [9] BIWEEKLY CISPLATIN AND GEMCITABINE AS FIRST-LINE TREATMENT IN ADVANCED NON-SMALL CELL LUNG CANCER
    Benekli, Mustafa
    Gunaydin, Yusuf
    Inanc, Mevlude
    Ozkan, Metin
    Demirci, Ayse
    Demirci, Umut
    Suner, Ali
    Karaca, Halit
    Tonyali, Onder
    Berk, Veli
    Buyukberber, Suleyman
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S563 - S563
  • [10] First-line treatment of advanced non-small-cell lung cancer (NSCLC) with vinorelbine and cisplatin.
    Bobilev, D
    Ariad, S
    Geffen, DB
    Cohen, Y
    [J]. ANNALS OF ONCOLOGY, 2000, 11 : 118 - 118
12345